Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Oliver John Kennedy,Michal Kicinski,Sara Valpione,Sara Gandini,Stefan Suciu,Christian U. Blank,Georgina V. Long,Victoria G. Atkinson,Stéphane Dalle, Andrew M. Haydon,Andrey Meshcheryakov, Adnan Khattak,Matteo S. Carlino,Shahneen Sandhu,James Larkin,Susana Puig,Paolo A. Ascierto,Piotr Rutkowski,Dirk Schadendorf, Marye Boers-Sonderen

European Journal of Cancer（2023）

引用 1|浏览0

暂无评分

摘要

•In the EORTC 1325/KEYNOTE-054 phase III trial, concomitant use of Metformin.•Was not significantly associated with recurrence-free survival (RFS).•Did not alter the treatment difference regarding RFS.•Did not shorten RFS in BRAF-mutated melanoma, as suggested by preclinical data.

查看译文

关键词

Melanoma,Immunotherapy,Metformin,Immunomodulation,BRAF

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要